Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 1월 2022 - 8:30PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that John Evans, chief executive officer, will present at
the 40th Annual J.P. Morgan Healthcare Conference on Monday,
January 10, 2022 at 2:15 p.m. ET.
A live webcast will be available in the investor section of the
company's website at www.beamtx.com, and will be archived for 60
days following the presentation.
About Beam TherapeuticsBeam Therapeutics
(Nasdaq: BEAM) is a biotechnology company committed to establishing
the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform
that includes a suite of gene editing and delivery technologies and
is in the process of building internal manufacturing capabilities.
Beam’s suite of gene editing technologies is anchored by base
editing, a proprietary technology that enables precise, predictable
and efficient single base changes, at targeted genomic sequences,
without making double-stranded breaks in the DNA. This enables a
wide range of potential therapeutic editing strategies that Beam is
using to advance a diversified portfolio of base editing programs.
Beam is a values-driven organization committed to its people,
cutting-edge science, and a vision of providing life-long cures to
patients suffering from serious diseases.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024